The World's Largest PDX and

primary 3d cell culture capability

140,000 viable, clinically annotated, primary human

tumors for pharmacology and biomarker studies

When: October 23rd, 10 am PST

Live with real time Q&A

Attend if you are interested in:

  • Transactional medicine
  • Biomarker discovery and validation
  • Pre-clinical models
  • Drug candidate prioritization
  • Patient stratification

Expert Speaker(s):

Tommy Broudy, Ph.D.

CSO, Molecular Response

Abstract

 

Dr. Broudy will discuss the use of patient-derived tumor banks to create more clinically-relevant in vivo and ex vivo models in support of oncology drug development. While cell line studies have been the main stay of oncology research for more than half a century, the ability to directly test drug efficacy on populations of patient tumors offers a translational approach toward forming more confident clinical development in the preclinical setting.

Recent advances in technology and method have enabled unprecedented science; ex vivo systems now combine 3D primary tumor cell culture with high content imaging, while in vivo systems rely on mouse hospitals featuring patient derived xenograft models in preclinical trial studies.

This webinar will focus on some of the advances our field have made to study the efficacy of anticancer agents before their actual trial in man–to identify successful indications, predictive markers of response, and effective combination therapies.

 

30 SECOND INFORMATION REQUEST FORM

  •  Indicates a required field
  • A valid email is required for delivery of your webinar access code